Immuno-Oncology Market Report 2025-2034
Immuno-Oncology Market Report 2025-2034
Segments - by Therapy Type (Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Others), by End-User (Hospitals, Cancer Research Centers, Clinics, Others)
Last Updated : Jun, 2026
| Report ID :HC-13899
| 5.0 Rating
| 5 Reviews
| 252 Pages
| Format :
Report Description
This report is updated with the latest market data and insights as of June 2026. Base year: 2025 | Forecast period: 2026-2034
Immuno-Oncology Market Outlook
According to our latest research, the global immuno-oncology market size reached USD 94.6 billion in 2025, reflecting robust momentum driven by ongoing advancements in cancer treatment and rising incidence rates worldwide. The market is expected to expand at a strong CAGR of 13.9% from 2026 to 2034, reaching a forecasted value of USD 322.8 billion by 2034. This impressive growth trajectory is underpinned by increasing adoption of immunotherapeutic approaches, expanding clinical applications, and significant investments in research and development. As per our latest research, the immuno-oncology market continues to evolve rapidly in 2025, with innovation and regulatory support fueling its expansion across key regions and therapeutic segments.
A major growth factor propelling the immuno-oncology market is the escalating global cancer burden. With an estimated 20 million new cancer cases diagnosed annually as of 2025, there is a critical demand for more effective and less toxic therapies. Immuno-oncology therapies, which harness the body's immune system to target and destroy cancer cells, have demonstrated superior efficacy and improved survival rates compared to traditional treatments. The rising prevalence of cancers such as lung, breast, and colorectal cancer is driving the adoption of immune checkpoint inhibitors, monoclonal antibodies, and cancer vaccines. Furthermore, the expanding approval of new indications for existing immunotherapies and the development of novel agents are broadening the scope of cancer immunotherapy, attracting significant attention from both clinicians and patients seeking improved outcomes.
Another significant driver is the surge in R&D activities and strategic collaborations between pharmaceutical companies, biotechnology firms, and academic institutions. The immuno-oncology landscape is characterized by a robust pipeline of investigational drugs, with hundreds of immuno-oncology clinical trials underway to evaluate the efficacy of various therapeutic modalities, including adoptive cell transfer and personalized cancer vaccines. These collaborations are accelerating the translation of scientific discoveries into innovative treatments, resulting in a steady stream of product launches and regulatory approvals. Additionally, government initiatives and funding support for cancer research are fostering an environment conducive to innovation, further reinforcing the growth prospects of the immuno-oncology market.
Technological advancements in biomarker discovery, genomics, and next-generation sequencing are also transforming the immuno-oncology market in 2025. These technologies are enabling the identification of patients who are most likely to benefit from immunotherapies, thereby enhancing treatment efficacy and minimizing adverse effects. The integration of artificial intelligence and machine learning in drug discovery and patient stratification is optimizing clinical trial design and accelerating the development of precision immunotherapies. As a result, pharmaceutical companies are increasingly investing in digital health solutions and companion diagnostics to support the adoption and reimbursement of immuno-oncology therapies, bolstering market growth. The broader application of these tools within precision oncology frameworks is further amplifying their impact on patient outcomes.
Regionally, North America dominates the immuno-oncology market due to its advanced healthcare infrastructure, high healthcare expenditure, and strong presence of leading biopharmaceutical companies. Europe follows closely, driven by supportive regulatory frameworks and increasing investments in cancer research. The Asia Pacific region is emerging as a high-growth market, fueled by rising cancer incidence, improving healthcare access, and growing awareness about immunotherapies. Latin America and the Middle East and Africa are also witnessing gradual adoption, supported by expanding healthcare infrastructure and international collaborations. These regional dynamics highlight the global appeal and transformative potential of immuno-oncology therapies in reshaping cancer care.
Nivolumab, marketed under the brand name Opdivo, is a groundbreaking immune checkpoint inhibitor developed by Bristol-Myers Squibb. It targets the PD-1 pathway, a critical checkpoint in the immune system, and has been instrumental in treating various cancers, including melanoma, lung cancer, and renal cell carcinoma. Now with well over a decade of real-world data supporting its clinical value, Nivolumab remains a cornerstone of combination immunotherapy regimens in 2025. Its success has spurred further research into combination approaches, where Nivolumab is paired with other immuno-oncology agents to enhance therapeutic outcomes. The drug's approvals spanning multiple indications underscore the versatility and growing acceptance of immunotherapies in mainstream cancer treatment globally.
Therapy Type Analysis
The therapy type segment of the immuno-oncology market is highly diversified, encompassing monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, adoptive cell transfer, and other emerging modalities. Immune checkpoint inhibitors now represent the largest therapy type segment as of 2025, accounting for approximately 34.5% of total market revenue, reflecting their widespread approval across more than 20 distinct cancer indications. Agents targeting the PD-1/PD-L1 and CTLA-4 pathways have demonstrated remarkable clinical success, particularly in melanoma, lung cancer, and solid tumors. The expanding approval of checkpoint inhibitors for new cancer types and earlier lines of therapy is fueling robust market growth, while combination strategies involving checkpoint inhibitors and other immunotherapies or conventional treatments are yielding improved response rates, further solidifying their position in the landscape.
Monoclonal antibodies constitute the second-largest segment, holding approximately 28.2% of market share in 2025, owing to their proven efficacy in targeting specific cancer antigens and their well-established role in treating various malignancies. These therapies have benefited from continuous innovation, with next-generation antibody-drug conjugates and bispecific formats offering enhanced specificity and reduced toxicity. The introduction of biosimilars for established monoclonal antibodies is expanding patient access and driving competitive pricing dynamics, particularly in European and Asia Pacific markets where cost considerations heavily influence treatment decisions.
Adoptive cell transfer therapies, including chimeric antigen receptor (CAR) T-cell therapy and tumor-infiltrating lymphocyte (TIL) therapy, hold approximately 17.4% of the therapy type market in 2025 and represent one of the fastest-growing sub-segments. CAR T-cell therapies have achieved notable success in treating certain types of leukemia, lymphoma, and multiple myeloma, leading to multiple regulatory approvals and active commercialization by leading players. TIL therapy has gained its own regulatory recognition, with the FDA approval of lifileucel marking a significant milestone for solid tumor applications. Ongoing research is focused on expanding applicability to a broader range of cancers and improving safety profiles through next-generation cell engineering strategies. The high cost and complex manufacturing processes associated with these therapies remain challenges, but advancements in automation and decentralized manufacturing are expected to drive future accessibility and growth. Research involving immuno-oncology co-culture models is also helping to accelerate preclinical evaluation of next-generation cell therapies.
Cancer vaccines represent a promising and revitalized frontier within the immuno-oncology market, accounting for approximately 11.6% of therapy type revenue in 2025. Both prophylactic and therapeutic vaccines are gaining traction, with personalized mRNA-based neoantigen vaccines showing particularly compelling data in late-stage clinical trials for melanoma and lung cancer. The validated success of mRNA platform technology during the COVID-19 pandemic has accelerated development timelines and investor confidence in this category. Advances in neoantigen prediction algorithms and high-throughput sequencing are enabling the rapid design of individualized vaccine constructs, bringing truly personalized cancer treatment closer to commercial reality.
Other emerging therapies, such as oncolytic viruses, bispecific T-cell engagers, and innate immune agonists, collectively represent approximately 8.3% of the therapy type market in 2025 and contribute meaningfully to the diversification of the immuno-oncology landscape. These innovative modalities are being explored in combination with established immunotherapies to enhance anti-tumor immune responses and overcome resistance mechanisms. The dynamic nature of this segment underscores the continuous evolution of the immuno-oncology field, with new approaches poised to address unmet clinical needs and expand the therapeutic arsenal against cancer well into the 2026-2034 forecast period.
Report Scope
| Attributes | Details |
| Report Title | Immuno-Oncology Market Research Report 2034 |
| By Therapy Type | Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines, Adoptive Cell Transfer, Others |
| By Application | Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Others |
| By End-User | Hospitals, Cancer Research Centers, Clinics, Others |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2025 |
| Historic Data | 2019-2024 |
| Forecast Period | 2026-2034 |
| Number of Pages | 252 |
| Number of Tables & Figures | 278 |
| Customization Available | Yes, the report can be customized as per your need. |
Application Analysis
The application segment of the immuno-oncology market is delineated by cancer type, with lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and other malignancies representing key therapeutic areas. Lung cancer remains the largest application segment in 2025, accounting for a significant proportion of immuno-oncology therapy utilization globally. The high incidence and mortality rates associated with lung cancer, coupled with the demonstrated efficacy of immune checkpoint inhibitors and monoclonal antibodies across both first and second-line settings, are driving widespread adoption. Ongoing clinical trials are exploring the use of immunotherapies in earlier stages of lung cancer and in perioperative settings, which is expected to further expand the patient pool and market potential through the 2026-2034 forecast period.
Breast cancer is another major application area, with immuno-oncology therapies increasingly integrated into treatment regimens for specific subtypes, most notably triple-negative breast cancer. The development of novel biomarkers and companion diagnostics is enabling the identification of patients most likely to benefit from immunotherapies, optimizing treatment outcomes and supporting reimbursement decisions. The success of combination strategies involving checkpoint inhibitors, antibody-drug conjugates, and chemotherapy is contributing to the growing adoption of immuno-oncology approaches in breast cancer management across major markets.
Colorectal cancer and melanoma represent additional high-value application segments within the immuno-oncology market. The advent of immunotherapies has fundamentally transformed the treatment landscape for metastatic melanoma, delivering durable remissions previously unachievable with chemotherapy. The use of immune checkpoint inhibitors in mismatch repair-deficient and microsatellite instability-high colorectal cancer has demonstrated substantial clinical benefit, prompting inclusion in major treatment guidelines worldwide. Research efforts are ongoing to extend the benefits of immunotherapies to other subtypes and earlier stages of these cancers, further enhancing their market impact across the forecast horizon.
Prostate cancer and other malignancies, including hematologic cancers and rare tumors, are increasingly being targeted by immuno-oncology therapies in 2025. Novel bispecific antibodies targeting PSMA and CD3 have shown meaningful clinical activity in metastatic castration-resistant prostate cancer, broadening the treatment landscape. The expansion of clinical indications and the development of next-generation agents are creating new opportunities for market growth. Personalized medicine approaches, such as the use of genetic and molecular profiling to guide therapy selection, are improving patient outcomes and driving adoption of immuno-oncology across a broader spectrum of cancer types, including applications now being explored in veterinary oncology.
Overall, the application segment reflects the versatility and expanding reach of immuno-oncology therapies in addressing diverse cancer types. The ongoing integration of immunotherapies into standard-of-care treatment protocols and the continuous generation of high-quality clinical evidence supporting their efficacy are expected to sustain robust growth across all major application areas throughout the 2026-2034 forecast period.
End-User Analysis
The end-user segment of the immuno-oncology market comprises hospitals, cancer research centers, clinics, and other healthcare facilities involved in the administration and management of immuno-oncology therapies. Hospitals represent the largest end-user segment in 2025, accounting for a substantial share of market revenue. This dominance is attributed to the availability of advanced infrastructure, multidisciplinary oncology care teams, and the capacity to manage complex immunotherapy regimens and associated immune-related adverse events. Hospitals also serve as primary sites for clinical trials and early adoption of new therapies, making them pivotal in the dissemination and uptake of immuno-oncology treatments across all major geographies.
Cancer research centers play a critical role in driving innovation and advancing the field of immuno-oncology. These institutions are at the forefront of basic and translational research, conducting early-phase clinical trials and developing novel therapeutic strategies. The collaboration between research centers, academic institutions, and industry partners is accelerating the discovery and commercialization of next-generation immunotherapies. The presence of specialized expertise and cutting-edge technologies in cancer research centers is fostering the development of personalized and precision medicine approaches, including the evaluation of advanced preclinical systems and next-generation treatment combinations.
Clinics, including outpatient oncology centers and specialty infusion clinics, are increasingly participating in the administration of immuno-oncology therapies in 2025. The ongoing shift toward outpatient care and the growing availability of well-tolerated immunotherapy regimens are enabling clinics to play a more prominent role in cancer treatment delivery. Clinics offer convenience, accessibility, and continuity of care for patients undergoing long-term immunotherapy maintenance regimens. The expansion of clinic-based immuno-oncology services is also contributing to the decentralization of cancer care, improving patient access and reducing the burden on hospital resources, particularly in suburban and semi-rural areas.
Other end-users, such as contract research organizations (CROs), specialty pharmacies, and home healthcare providers, are also contributing to the growth of the immuno-oncology market. CROs are supporting the design and execution of clinical trials, facilitating regulatory submissions, and expediting the development of new therapies. Specialty pharmacies are involved in the distribution and management of complex immunotherapies, ensuring safe and timely delivery to patients. The emergence of home-based immunotherapy administration and remote patient monitoring solutions is further expanding the reach of immuno-oncology treatments, particularly for patients with mobility challenges or those residing in areas with limited specialist access.
The end-user landscape is characterized by increasing collaboration and integration across different healthcare settings, aimed at optimizing patient outcomes and streamlining the delivery of immuno-oncology therapies. The adoption of multidisciplinary care models, the implementation of digital health solutions, and the emphasis on patient-centered care are expected to shape the future trajectory of the end-user segment, supporting the sustained growth of the immuno-oncology market through 2034.
Opportunities & Threats
The immuno-oncology market presents significant opportunities for growth in 2025 and beyond, driven by an expanding pipeline of innovative therapies and the increasing adoption of combination approaches. The development of novel immune checkpoint inhibitors, bispecific antibodies, and mRNA-based personalized cancer vaccines is creating new avenues for therapeutic intervention across previously intractable cancer types. Advances in biomarker discovery and companion diagnostics are enabling identification of patient subgroups most likely to benefit from immunotherapies, enhancing treatment efficacy and supporting favorable reimbursement decisions. The integration of artificial intelligence and machine learning in drug discovery, patient stratification, and clinical trial design is accelerating the development and approval of new immuno-oncology agents. The growing focus on precision medicine and the emergence of next-generation sequencing technologies are supporting the customization of immuno-oncology treatments and further expanding the market's potential within broader oncology therapeutics portfolios.
Another major opportunity lies in the increasing penetration of immuno-oncology therapies in emerging markets. As healthcare infrastructure and cancer care capabilities improve in regions such as Asia Pacific, Latin America, and the Middle East and Africa, there is a growing demand for advanced cancer therapies. Governments and healthcare organizations in these regions are investing in cancer screening, early diagnosis, and comprehensive treatment programs, creating a favorable environment for the adoption of immuno-oncology therapies. International collaborations, technology transfer agreements, and local manufacturing initiatives are also supporting market expansion. The rising incidence of cancer, coupled with increasing clinician and patient awareness about the benefits of immunotherapies, is expected to drive substantial growth in emerging markets over the 2026-2034 forecast period.
Despite these opportunities, the immuno-oncology market faces certain restraining factors, most notably the high cost and complexity of advanced immunotherapy treatments. The development, manufacturing, and administration of therapies such as CAR T-cell products and personalized cancer vaccines require significant resources and specialized infrastructure, resulting in high price points that limit accessibility in low- and middle-income countries. Reimbursement challenges, regulatory hurdles, and concerns about long-term safety, immune-related toxicity, and therapy resistance also pose barriers to widespread adoption. Addressing these challenges will require concerted efforts from stakeholders across the healthcare ecosystem, including policymakers, payers, and industry players, to ensure equitable access to life-saving immuno-oncology treatments globally.
Regional Outlook
North America continues to lead the immuno-oncology market, accounting for approximately 42.1% of global revenue in 2025, translating to a market size of approximately USD 39.8 billion. The region's dominance is driven by advanced healthcare infrastructure, high levels of healthcare spending, and the concentration of leading pharmaceutical and biotechnology companies. The United States remains a primary global hub for immuno-oncology research, clinical trials, and product launches, supported by the FDA's expedited approval pathways including Breakthrough Therapy Designation and Accelerated Approval. The region is expected to maintain its leadership position over the 2026-2034 forecast period, with a projected CAGR of 13.1%.
Europe is the second-largest market for immuno-oncology, representing approximately 23.8% of global revenue in 2025, equivalent to a market size of approximately USD 22.5 billion. The region benefits from robust healthcare systems, extensive cancer research networks, and favorable reimbursement frameworks for innovative therapies. Germany, the United Kingdom, and France are at the forefront of immuno-oncology adoption, supported by strong collaborations between academia, industry, and government agencies. The European Medicines Agency has played a pivotal role in accelerating approvals of new immuno-oncology therapies through its PRIME scheme, and the region is expected to grow steadily driven by increasing investments in cancer research and expanding use of immunotherapies across major cancer types through 2034.
The Asia Pacific region is emerging as the fastest-growing market within global immuno-oncology, representing approximately 21.4% of market share in 2025 and an estimated market size of USD 20.2 billion. Rapidly rising cancer incidence, improving healthcare infrastructure, and growing awareness about advanced cancer treatments are driving demand in China, Japan, India, and South Korea. The region is witnessing increasing participation in global clinical trials, growing local manufacturing capabilities, and strategic partnerships between multinational and regional players. Government initiatives to enhance cancer care access and promote innovative therapies are further supporting market expansion. Asia Pacific is expected to register the highest CAGR among all regions during the 2026-2034 forecast period, underscoring its growing strategic significance for global immuno-oncology market participants.
Competitor Outlook
The immuno-oncology market in 2025 is characterized by intense competition and a dynamic landscape, with both established pharmaceutical giants and innovative biotechnology firms vying for market leadership. The competitive environment is shaped by continuous R&D investments, strategic alliances, mergers and acquisitions, and a relentless focus on differentiated innovation. Companies are expanding their immuno-oncology portfolios through the development of novel agents, combination therapies, and next-generation technologies including bispecific antibodies, antibody-drug conjugates, and cell therapies. The race to bring first-in-class and best-in-class immunotherapies to market is driving rapid progress, with a steady stream of product launches and regulatory approvals reshaping competitive dynamics year over year.
Market leaders are leveraging their extensive research capabilities, global commercial reach, and financial resources to maintain competitive advantage. These companies are actively involved in clinical trials spanning multiple cancer types and therapeutic modalities, often collaborating with academic institutions, research centers, and smaller biotech firms. The emphasis on precision medicine and personalized immunotherapy is prompting investment in companion diagnostics, biomarker development, and digital health solutions. The ability to demonstrate superior clinical outcomes, acceptable safety profiles, and cost-effectiveness is increasingly becoming a key differentiator, particularly as payers demand robust real-world evidence to support reimbursement decisions.
The competitive landscape is further enriched by the entry of emerging players and startups focused on disruptive technologies, including in vivo CAR T approaches, mRNA cancer vaccines, and novel innate immune pathway agonists. These companies are attracting significant venture capital and strategic investment while forging partnerships with larger industry players to accelerate development and commercialization. The growing emphasis on open innovation, platform licensing, and cross-border collaboration is fostering a vibrant ecosystem that supports the continuous evolution of the immuno-oncology market through 2034.
Major companies operating in the immuno-oncology market include Bristol-Myers Squibb, Merck and Co., Roche, Novartis, AstraZeneca, Pfizer, and Gilead Sciences, among others. Bristol-Myers Squibb remains a pioneer in immune checkpoint inhibition, with Opdivo (nivolumab) and Yervoy (ipilimumab) widely used across multiple cancer types and the company investing heavily in next-generation combinations. Merck and Co. drives substantial revenue through Keytruda (pembrolizumab), which maintains its position as the world's leading immuno-oncology drug by sales in 2025, with approvals spanning more than 40 distinct indications. Roche leads in monoclonal antibodies and antibody-drug conjugates, leveraging its expansive oncology pipeline and integrated diagnostic capabilities. Novartis and Gilead Sciences maintain frontrunner positions in CAR T-cell therapies through Kymriah and Yescarta respectively, while AstraZeneca and Eli Lilly are investing aggressively in next-generation agents and combination strategies. Moderna, in partnership with Merck, is advancing personalized mRNA cancer vaccines, representing one of the most closely watched clinical programs in the sector. BeiGene continues to expand its global footprint with competitive checkpoint inhibitor and BTK inhibitor portfolios, reinforcing the increasingly global and competitive nature of the immuno-oncology market heading into the 2026-2034 forecast period.
Key Players
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Roche Holding AG
- Novartis AG
- AstraZeneca plc
- Pfizer Inc.
- Johnson & Johnson
- Amgen Inc.
- Gilead Sciences, Inc.
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Incyte Corporation
- BeiGene Ltd.
- Moderna, Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
Segments
The Immuno-Oncology market has been segmented on the basis of
Therapy Type
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Cancer Vaccines
- Adoptive Cell Transfer
- Others
Application
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Others
End-User
- Hospitals
- Cancer Research Centers
- Clinics
- Others
Frequently Asked Questions
Hospitals are the dominant end-users of immuno-oncology therapies in 2025, capturing the largest revenue share due to their capacity to manage complex treatment regimens, handle serious immune-related adverse events, and host clinical trials. Academic medical centers and dedicated cancer research centers are critical sites for translational research, early-phase trials, and the development of novel therapeutic protocols. Specialty oncology clinics and outpatient infusion centers are increasingly administering established checkpoint inhibitor regimens as care shifts toward ambulatory settings, improving patient convenience and reducing healthcare costs. Specialty pharmacies play a growing role in the distribution of oral and complex biologics. Contract research organizations support clinical development activities globally. Emerging telehealth and home infusion platforms are beginning to extend the reach of select immuno-oncology therapies to patients in remote or underserved locations, reflecting broader trends toward decentralized and patient-centered care models.
Technological innovation is reshaping the immuno-oncology market across every stage of drug development and delivery in 2025. Advances in immuno-oncology biomarker discovery are enabling increasingly precise patient selection, improving response rates, and supporting companion diagnostic development. mRNA platform technologies, validated at scale during the COVID-19 pandemic, are being applied to personalized neoantigen cancer vaccines, with late-stage trials from Moderna and BioNTech showing promising efficacy signals. Artificial intelligence and machine learning tools are transforming drug target identification, clinical trial design, and the use of AI-powered trial matching platforms that connect eligible patients with appropriate studies. Next-generation sequencing and spatial transcriptomics are deepening understanding of tumor microenvironments. Automated and closed-system cell manufacturing platforms are improving the scalability and consistency of CAR T-cell production. Bispecific antibodies and antibody-drug conjugates represent additional technological frontiers driving pipeline expansion.
Despite strong growth prospects, the immuno-oncology market faces several significant challenges as of 2025. High therapy costs, particularly for CAR T-cell treatments and personalized cancer vaccines that can exceed USD 400,000 per patient course, limit access in low- and middle-income countries and strain healthcare payer systems globally. Immune-related adverse events associated with checkpoint inhibitors can be severe, requiring vigilant patient monitoring and specialist management. Primary and acquired resistance to immunotherapies remains a major clinical obstacle, with many patients either not responding initially or relapsing after initial benefit. The complexity of manufacturing cell and gene therapies at commercial scale continues to pressure supply chains and cost structures. Heterogeneous reimbursement landscapes across markets create access disparities. Competitive saturation in the checkpoint inhibitor segment is intensifying pricing pressure. Regulatory requirements for robust real-world evidence and long-term safety data are adding to commercialization complexity.
Several interconnected factors are propelling the immuno-oncology market forward in 2025. The escalating global cancer burden, with an estimated 20 million new cases diagnosed annually, is creating persistent and growing demand for effective therapies beyond conventional chemotherapy. The broad and expanding clinical validation of checkpoint inhibitors, CAR T-cell therapies, and bispecific antibodies across dozens of cancer types is widening the addressable market. Regulatory tailwinds, including FDA Breakthrough Therapy Designation, Accelerated Approval, and EMA PRIME schemes, are shortening development timelines. Strategic collaborations between large pharmaceutical companies, biotech startups, and academic medical centers are enriching the pipeline. The rise of precision oncology, supported by advances in biomarker testing and next-generation sequencing, is enabling better patient selection and higher response rates. Artificial intelligence applications in drug discovery and clinical trial design are also accelerating development cycles and reducing costs.
The global immuno-oncology market in 2025 is led by a combination of large-cap biopharmaceutical companies and innovative biotechnology firms. Bristol-Myers Squibb, the pioneer of immune checkpoint inhibition through Opdivo (nivolumab) and Yervoy (ipilimumab), remains a dominant force. Merck and Co. drives substantial revenue through Keytruda (pembrolizumab), the world's highest-selling immuno-oncology agent. Roche and its subsidiary Genentech maintain a strong position through Tecentriq (atezolizumab) and a broad antibody-drug conjugate portfolio. AstraZeneca competes effectively with Imfinzi (durvalumab) and Tagrisso combinations. Novartis and Gilead Sciences are leaders in CAR T-cell therapies through Kymriah and Yescarta respectively. Moderna is advancing mRNA-based personalized cancer vaccines in collaboration with Merck. BeiGene, Regeneron, Eli Lilly, Sanofi, AbbVie, Incyte, GlaxoSmithKline, Amgen, Pfizer, Johnson and Johnson, and Takeda also hold significant and growing positions across various therapy types and indications.
North America holds the largest regional share of the global immuno-oncology market in 2025, accounting for approximately 42.1% of total revenue. The United States is the primary driver, benefiting from world-class biopharmaceutical infrastructure, FDA expedited approval pathways, high healthcare spending, and a large patient population. Europe is the second-largest region with a 23.8% share, led by Germany, the United Kingdom, and France, supported by the European Medicines Agency's progressive regulatory stance and robust national cancer research networks. Asia Pacific is the fastest-growing region, representing 21.4% of the market in 2025 and expected to register the highest CAGR through 2034, driven by surging cancer incidence in China, Japan, India, and South Korea alongside expanding healthcare infrastructure and government-backed cancer initiatives. Latin America and the Middle East and Africa each contribute meaningfully and are projected to grow steadily as healthcare access improves.
The immuno-oncology landscape in 2025 comprises five principal therapy categories. Immune checkpoint inhibitors, targeting PD-1, PD-L1, and CTLA-4 pathways, represent the largest and most commercially mature segment, with agents such as pembrolizumab and nivolumab approved across dozens of indications. Monoclonal antibodies targeting tumor-associated antigens, including naked antibodies and antibody-drug conjugates, constitute the second major segment. Adoptive cell transfer therapies, particularly CAR T-cell products and the emerging tumor-infiltrating lymphocyte (TIL) therapy segment exemplified by lifileucel, are gaining significant traction. Cancer vaccines, including prophylactic HPV vaccines and investigational personalized mRNA-based neoantigen vaccines, form the fourth category. Other modalities such as oncolytic viruses, bispecific antibodies, and innate immune agonists round out the therapeutic landscape, many of which are in advanced clinical development as of 2025.
As of 2025, lung cancer remains the single largest application area for immuno-oncology therapies, reflecting both the high global incidence of the disease and the well-established efficacy of PD-1/PD-L1 checkpoint inhibitors in non-small cell lung cancer. Melanoma was historically among the first indications to benefit from checkpoint inhibition and continues to be a reference indication for combination immunotherapy strategies. Breast cancer, particularly triple-negative breast cancer, has become an increasingly important segment following approvals of atezolizumab and pembrolizumab in specific biomarker-selected populations. Colorectal cancer with mismatch repair deficiency, hematologic malignancies such as diffuse large B-cell lymphoma and multiple myeloma, renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma are also major application areas. Prostate cancer and rare tumor types represent emerging frontiers as novel agents and combination regimens are evaluated in ongoing trials.
According to our latest research, the global immuno-oncology market reached USD 94.6 billion in 2025, establishing a strong base driven by rising cancer incidence, accelerating regulatory approvals, and widening clinical adoption of checkpoint inhibitors, CAR T-cell therapies, and cancer vaccines. The market is projected to expand at a robust CAGR of 13.9% over the 2026-2034 forecast period, reaching an estimated USD 322.8 billion by 2034. This trajectory reflects sustained investment in R&D, the entry of next-generation agents, growing penetration in emerging markets, and the continued integration of immuno-oncology into standard-of-care treatment guidelines across major cancer indications globally.
Immuno-oncology is a branch of cancer medicine that harnesses the body's own immune system to detect, attack, and eliminate cancer cells. Unlike conventional chemotherapy or radiation, which act directly on tumor tissue, immuno-oncology therapies work by removing the molecular brakes that tumors impose on immune cells, engineering immune cells to better recognize cancer antigens, or teaching the immune system to mount a durable anti-tumor response. Key mechanisms include blocking inhibitory checkpoint proteins such as PD-1, PD-L1, and CTLA-4, introducing chimeric antigen receptor (CAR) T-cells, and delivering cancer vaccines that prime the immune system against tumor-specific neoantigens. As of 2025, immuno-oncology encompasses a broad and rapidly expanding portfolio of modalities that are increasingly used as first-line and combination treatments across many cancer types.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Immuno-Oncology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Immuno-Oncology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Immuno-Oncology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Immuno-Oncology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Immuno-Oncology Market Size & Forecast, 2023-2032
4.5.1 Immuno-Oncology Market Size and Y-o-Y Growth
4.5.2 Immuno-Oncology Market Absolute $ Opportunity
Chapter 5 Global Immuno-Oncology Market Analysis and Forecast By Therapy Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Therapy Type
5.1.2 Basis Point Share (BPS) Analysis By Therapy Type
5.1.3 Absolute $ Opportunity Assessment By Therapy Type
5.2 Immuno-Oncology Market Size Forecast By Therapy Type
5.2.1 Monoclonal Antibodies
5.2.2 Immune Checkpoint Inhibitors
5.2.3 Cancer Vaccines
5.2.4 Adoptive Cell Transfer
5.2.5 Others
5.3 Market Attractiveness Analysis By Therapy Type
Chapter 6 Global Immuno-Oncology Market Analysis and Forecast By Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Application
6.1.2 Basis Point Share (BPS) Analysis By Application
6.1.3 Absolute $ Opportunity Assessment By Application
6.2 Immuno-Oncology Market Size Forecast By Application
6.2.1 Lung Cancer
6.2.2 Breast Cancer
6.2.3 Colorectal Cancer
6.2.4 Melanoma
6.2.5 Prostate Cancer
6.2.6 Others
6.3 Market Attractiveness Analysis By Application
Chapter 7 Global Immuno-Oncology Market Analysis and Forecast By End-User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End-User
7.1.2 Basis Point Share (BPS) Analysis By End-User
7.1.3 Absolute $ Opportunity Assessment By End-User
7.2 Immuno-Oncology Market Size Forecast By End-User
7.2.1 Hospitals
7.2.2 Cancer Research Centers
7.2.3 Clinics
7.2.4 Others
7.3 Market Attractiveness Analysis By End-User
Chapter 8 Global Immuno-Oncology Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By Region
8.1.2 Basis Point Share (BPS) Analysis By Region
8.1.3 Absolute $ Opportunity Assessment By Region
8.2 Immuno-Oncology Market Size Forecast By Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis By Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Immuno-Oncology Analysis and Forecast
10.1 Introduction
10.2 North America Immuno-Oncology Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Immuno-Oncology Market Size Forecast By Therapy Type
10.6.1 Monoclonal Antibodies
10.6.2 Immune Checkpoint Inhibitors
10.6.3 Cancer Vaccines
10.6.4 Adoptive Cell Transfer
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis By Therapy Type
10.8 Absolute $ Opportunity Assessment By Therapy Type
10.9 Market Attractiveness Analysis By Therapy Type
10.10 North America Immuno-Oncology Market Size Forecast By Application
10.10.1 Lung Cancer
10.10.2 Breast Cancer
10.10.3 Colorectal Cancer
10.10.4 Melanoma
10.10.5 Prostate Cancer
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis By Application
10.12 Absolute $ Opportunity Assessment By Application
10.13 Market Attractiveness Analysis By Application
10.14 North America Immuno-Oncology Market Size Forecast By End-User
10.14.1 Hospitals
10.14.2 Cancer Research Centers
10.14.3 Clinics
10.14.4 Others
10.15 Basis Point Share (BPS) Analysis By End-User
10.16 Absolute $ Opportunity Assessment By End-User
10.17 Market Attractiveness Analysis By End-User
Chapter 11 Europe Immuno-Oncology Analysis and Forecast
11.1 Introduction
11.2 Europe Immuno-Oncology Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Immuno-Oncology Market Size Forecast By Therapy Type
11.6.1 Monoclonal Antibodies
11.6.2 Immune Checkpoint Inhibitors
11.6.3 Cancer Vaccines
11.6.4 Adoptive Cell Transfer
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis By Therapy Type
11.8 Absolute $ Opportunity Assessment By Therapy Type
11.9 Market Attractiveness Analysis By Therapy Type
11.10 Europe Immuno-Oncology Market Size Forecast By Application
11.10.1 Lung Cancer
11.10.2 Breast Cancer
11.10.3 Colorectal Cancer
11.10.4 Melanoma
11.10.5 Prostate Cancer
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis By Application
11.12 Absolute $ Opportunity Assessment By Application
11.13 Market Attractiveness Analysis By Application
11.14 Europe Immuno-Oncology Market Size Forecast By End-User
11.14.1 Hospitals
11.14.2 Cancer Research Centers
11.14.3 Clinics
11.14.4 Others
11.15 Basis Point Share (BPS) Analysis By End-User
11.16 Absolute $ Opportunity Assessment By End-User
11.17 Market Attractiveness Analysis By End-User
Chapter 12 Asia Pacific Immuno-Oncology Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Immuno-Oncology Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Immuno-Oncology Market Size Forecast By Therapy Type
12.6.1 Monoclonal Antibodies
12.6.2 Immune Checkpoint Inhibitors
12.6.3 Cancer Vaccines
12.6.4 Adoptive Cell Transfer
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis By Therapy Type
12.8 Absolute $ Opportunity Assessment By Therapy Type
12.9 Market Attractiveness Analysis By Therapy Type
12.10 Asia Pacific Immuno-Oncology Market Size Forecast By Application
12.10.1 Lung Cancer
12.10.2 Breast Cancer
12.10.3 Colorectal Cancer
12.10.4 Melanoma
12.10.5 Prostate Cancer
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis By Application
12.12 Absolute $ Opportunity Assessment By Application
12.13 Market Attractiveness Analysis By Application
12.14 Asia Pacific Immuno-Oncology Market Size Forecast By End-User
12.14.1 Hospitals
12.14.2 Cancer Research Centers
12.14.3 Clinics
12.14.4 Others
12.15 Basis Point Share (BPS) Analysis By End-User
12.16 Absolute $ Opportunity Assessment By End-User
12.17 Market Attractiveness Analysis By End-User
Chapter 13 Latin America Immuno-Oncology Analysis and Forecast
13.1 Introduction
13.2 Latin America Immuno-Oncology Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Immuno-Oncology Market Size Forecast By Therapy Type
13.6.1 Monoclonal Antibodies
13.6.2 Immune Checkpoint Inhibitors
13.6.3 Cancer Vaccines
13.6.4 Adoptive Cell Transfer
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis By Therapy Type
13.8 Absolute $ Opportunity Assessment By Therapy Type
13.9 Market Attractiveness Analysis By Therapy Type
13.10 Latin America Immuno-Oncology Market Size Forecast By Application
13.10.1 Lung Cancer
13.10.2 Breast Cancer
13.10.3 Colorectal Cancer
13.10.4 Melanoma
13.10.5 Prostate Cancer
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis By Application
13.12 Absolute $ Opportunity Assessment By Application
13.13 Market Attractiveness Analysis By Application
13.14 Latin America Immuno-Oncology Market Size Forecast By End-User
13.14.1 Hospitals
13.14.2 Cancer Research Centers
13.14.3 Clinics
13.14.4 Others
13.15 Basis Point Share (BPS) Analysis By End-User
13.16 Absolute $ Opportunity Assessment By End-User
13.17 Market Attractiveness Analysis By End-User
Chapter 14 Middle East & Africa (MEA) Immuno-Oncology Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Immuno-Oncology Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Immuno-Oncology Market Size Forecast By Therapy Type
14.6.1 Monoclonal Antibodies
14.6.2 Immune Checkpoint Inhibitors
14.6.3 Cancer Vaccines
14.6.4 Adoptive Cell Transfer
14.6.5 Others
14.7 Basis Point Share (BPS) Analysis By Therapy Type
14.8 Absolute $ Opportunity Assessment By Therapy Type
14.9 Market Attractiveness Analysis By Therapy Type
14.10 Middle East & Africa (MEA) Immuno-Oncology Market Size Forecast By Application
14.10.1 Lung Cancer
14.10.2 Breast Cancer
14.10.3 Colorectal Cancer
14.10.4 Melanoma
14.10.5 Prostate Cancer
14.10.6 Others
14.11 Basis Point Share (BPS) Analysis By Application
14.12 Absolute $ Opportunity Assessment By Application
14.13 Market Attractiveness Analysis By Application
14.14 Middle East & Africa (MEA) Immuno-Oncology Market Size Forecast By End-User
14.14.1 Hospitals
14.14.2 Cancer Research Centers
14.14.3 Clinics
14.14.4 Others
14.15 Basis Point Share (BPS) Analysis By End-User
14.16 Absolute $ Opportunity Assessment By End-User
14.17 Market Attractiveness Analysis By End-User
Chapter 15 Competition Landscape
15.1 Immuno-Oncology Market: Competitive Dashboard
15.2 Global Immuno-Oncology Market: Market Share Analysis, 2023
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Bristol-Myers Squibb
15.3.2 Merck & Co., Inc.
15.3.3 Roche Holding AG
15.3.4 Novartis AG
15.3.5 AstraZeneca plc
15.3.6 Pfizer Inc.
15.3.7 Johnson & Johnson
15.3.8 Amgen Inc.
15.3.9 Gilead Sciences, Inc.
15.3.10 Eli Lilly and Company
15.3.11 Regeneron Pharmaceuticals, Inc.
15.3.12 AbbVie Inc.
15.3.13 Takeda Pharmaceutical Company Limited
15.3.14 Incyte Corporation
15.3.15 BeiGene Ltd.
15.3.16 Moderna, Inc.
15.3.17 Sanofi S.A.
15.3.18 GlaxoSmithKline plc
Methodology
Related Reports
Some other reports from this category!
Our Clients
